Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IACH 2021 | Post-transplant cyclophosphamide in chronic GvHD

Arnon Nagler • 23 Sep 2021
IACH 2021
General Cyclophosphamide

Arnon Nagler, MD, MSc, Chaim Sheba Medical Center, Tel-Hashomer, Israel, gives an overview of the latest advances in the treatment of chronic graft-versus-host disease (GvHD). Post-transplant cyclophosphamide has been critical in reducing chronic GvHD following haploidentical and unrelated transplants. Several studies have shown that there was no higher relapse rate amongst patients who received haploidentical transplants with post-transplant cyclophosphamide compared to conventional drugs used in GvHD prophylaxis. This interview took place at the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH), which took place virtually in 2021.

Disclosures

Arnon Nagler, MD, MSc, is the Co-Chair, Co-Organizer and Co-Founder of the International Academy for Clinical Hematology (IACH),

More from Arnon Nagler

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:21
Trends in alloSCT for good-risk AML: a longitudinal study
Arnon Nagler • 9 Dec 2023
2:15
GvHD prophylaxis post-alloSCT: PTCy versus ATG
Arnon Nagler • 9 Dec 2023
2:13
Haploidentical SCT for the treatment of secondary AML
Arnon Nagler • 9 Dec 2023

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals